{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T21:43:38Z","timestamp":1771623818564,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:00:00Z","timestamp":1536105600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00592-018-1220-1","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T03:00:45Z","timestamp":1536116445000},"page":"97-104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Activation of angiotensin type 2 (AT2) receptors prevents myocardial hypertrophy in Zucker diabetic fatty rats"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5295-6942","authenticated-orcid":false,"given":"Giovanna","family":"Castoldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cira R. T.","family":"di Gioia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Roma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Carletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Manzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpaolo","family":"Zerbini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Perseghin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,5]]},"reference":[{"key":"1220_CR1","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2337\/dc11-0442","volume":"34","author":"FB Hu","year":"2011","unstructured":"Hu FB (2011) Globalization of diabetes. The role of diet, lifestyle, and genes. Diabetes Care 34:1249\u20131257. \n                    https:\/\/doi.org\/10.2337\/dc11-0442","journal-title":"Diabetes Care"},{"key":"1220_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2213-8587(13)70112-8","volume":"2","author":"PZ Zimmet","year":"2014","unstructured":"Zimmet PZ, Magliano DJ, Herman WH, Shaw JE (2014) Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2:56\u201364. \n                    https:\/\/doi.org\/10.1016\/S2213-8587(13)70112-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1220_CR3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"UKPDS Group","year":"1998","unstructured":"UKPDS Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703\u2013713","journal-title":"BMJ"},{"key":"1220_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/DMSO.S61438","volume":"7","author":"D Lorber","year":"2014","unstructured":"Lorber D (2014) Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 7:169\u2013183. \n                    https:\/\/doi.org\/10.2147\/DMSO.S61438","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1220_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00125-017-4390-4","volume":"61","author":"G Jia","year":"2018","unstructured":"Jia G, Whaley-Connell A, Sowers JR (2018) Diabetic cardiomyopathy: a hyperglycaemia and insulin-resistance-induced heart disease. Diabetologia 61:21\u201328. \n                    https:\/\/doi.org\/10.1007\/s00125-017-4390-4","journal-title":"Diabetologia"},{"key":"1220_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0008-6363(98)00186-2","volume":"40","author":"NS Dhalla","year":"1998","unstructured":"Dhalla NS, Liu X, Panagia V, Takeda N (1998) Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 40:239\u2013247","journal-title":"Cardiovasc Res"},{"key":"1220_CR7","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","volume":"31","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31:1281\u20131357. \n                    https:\/\/doi.org\/10.1097\/01.hjh.0000431740.32696.cc","journal-title":"J Hypertens"},{"key":"1220_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s40292-015-0120-5","volume":"22","author":"C Borghi","year":"2015","unstructured":"Borghi C, SIIA Task Force, Rossi F, SIF Task Force (2015) Role of the renin-angiotensin-aldosterone system and its pharmacological inhibitors in cardiovascular diseases: complex and critical issues. High Blood Press Cardiovasc Prev 22:429\u2013444. \n                    https:\/\/doi.org\/10.1007\/s40292-015-0120-5","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"1220_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11906-012-0321-4","volume":"15","author":"CA McCarthy","year":"2013","unstructured":"McCarthy CA, Widdop RE, Denton KM, Jones ES (2013) Update on the angiotensin AT2 receptor. Curr Hypertens Rep 15:25\u201330. \n                    https:\/\/doi.org\/10.1007\/s11906-012-0321-4","journal-title":"Curr Hypertens Rep"},{"key":"1220_CR10","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/ki.2013.193","volume":"84","author":"Q Ali","year":"2013","unstructured":"Ali Q, Wu Y, Hussain T (2013) Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats. Kidney Int 84:931\u2013939. \n                    https:\/\/doi.org\/10.1038\/ki.2013.193","journal-title":"Kidney Int"},{"key":"1220_CR11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1161\/HYPERTENSIONAHA.109.147843","volume":"55","author":"F Rompe","year":"2010","unstructured":"Rompe F, Artuc M, Hallberg A et al (2010) Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 55:924\u2013931. \n                    https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.147843","journal-title":"Hypertension"},{"key":"1220_CR12","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1161\/CIRCULATIONAHA.108.784868","volume":"118","author":"E Kaschina","year":"2008","unstructured":"Kaschina E, Grzesiak A, Li J et al (2008) Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 118:2523\u20132532. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.784868","journal-title":"Circulation"},{"key":"1220_CR13","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1161\/HYPERTENSIONAHA.113.02522","volume":"63","author":"D Lauer","year":"2014","unstructured":"Lauer D, Slavic S, Sommerfeld M et al (2014) Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1\/matrix metalloproteinase 9 axis and transforming growth factor \u03b21 in the rat heart. Hypertension 63:e60\u2013e67. \n                    https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.02522","journal-title":"Hypertension"},{"key":"1220_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1470320309347792","volume":"11","author":"T Unger","year":"2010","unstructured":"Unger T, Dahl\u00f6f B (2010) Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential. J Renin Angiotensin Aldosterone Syst 11:75\u201377. \n                    https:\/\/doi.org\/10.1177\/1470320309347792","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"1220_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.phrs.2017.07.008","volume":"125","author":"E Kaschina","year":"2017","unstructured":"Kaschina E, Namsolleck P, Unger T (2017) AT2 receptors in cardiovascular and renal diseases. Pharmacol Res 125:39\u201347. \n                    https:\/\/doi.org\/10.1016\/j.phrs.2017.07.008","journal-title":"Pharmacol Res"},{"key":"1220_CR16","doi-asserted-by":"publisher","first-page":"e00403","DOI":"10.1042\/BSR20160278","volume":"36","author":"G Castoldi","year":"2016","unstructured":"Castoldi G, di Gioia CR, Carletti R et al (2016) Angiotensin type-2 (AT-2)-receptor activation reduces renal fibrosis in cyclosporine nephropathy: evidence for blood-pressure independent effect. Biosci Rep 36:e00403. \u00a0\n                    https:\/\/doi.org\/10.1042\/BSR20160278","journal-title":"Biosci Rep"},{"key":"1220_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1161\/HYPERTENSIONAHA.111.185496","volume":"59","author":"L Paulis","year":"2012","unstructured":"Paulis L, Becker ST, Lucht K et al (2012) Direct angiotensin II type 2 receptor stimulation in N\u03c9-nitro-L-arginine-methyl ester-induced hypertension. The effect on pulse wave velocity and aortic remodeling. Hypertension 59:485\u2013492. \n                    https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.185496","journal-title":"Hypertension"},{"key":"1220_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1161\/HYPERTENSIONAHA.111.180158","volume":"59","author":"A Rehman","year":"2012","unstructured":"Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P, Schiffrin EL (2012) Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 59:291\u2013299. \n                    https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.180158","journal-title":"Hypertension"},{"key":"1220_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281\u2013297","journal-title":"Cell"},{"key":"1220_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrg2936","volume":"12","author":"E Huntzinger","year":"2011","unstructured":"Huntzinger E, Izaurralde E (2011) Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 12:99\u2013110. \n                    https:\/\/doi.org\/10.1038\/nrg2936","journal-title":"Nat Rev Genet"},{"key":"1220_CR21","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nature09267","volume":"466","author":"H Guo","year":"2010","unstructured":"Guo H, Ingolia NT, Weissman JS, Bartel DP (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466:835\u2013840. \n                    https:\/\/doi.org\/10.1038\/nature09267","journal-title":"Nature"},{"key":"1220_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1161\/CIRCRESAHA.108.182535","volume":"104","author":"RF Duisters","year":"2009","unstructured":"Duisters RF, Tijsen AJ, Schroen B et al (2009) miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 104:170\u2013178. \n                    https:\/\/doi.org\/10.1161\/CIRCRESAHA.108.182535","journal-title":"Circ Res"},{"key":"1220_CR23","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/jcp.22939","volume":"227","author":"G Castoldi","year":"2012","unstructured":"Castoldi G, Di Gioia CR, Bombardi C et al (2012) MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. J Cell Physiol 227:850\u2013856. \n                    https:\/\/doi.org\/10.1002\/jcp.22939","journal-title":"J Cell Physiol"},{"key":"1220_CR24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.yjmcc.2016.08.016","volume":"99","author":"X Guan","year":"2016","unstructured":"Guan X, Wang L, Liu Z et al (2016) miR-106a promotes cardiac hypertrophy by targeting mitofusin 2. J Mol Cell Cardiol 99:207\u2013217. \n                    https:\/\/doi.org\/10.1016\/j.yjmcc.2016.08.016","journal-title":"J Mol Cell Cardiol"},{"key":"1220_CR25","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00125-015-3622-8","volume":"58","author":"D Zheng","year":"2015","unstructured":"Zheng D, Ma J, Yu Y et al (2015) Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL\/6 mice. Diabetologia 58:1949\u20131958. \n                    https:\/\/doi.org\/10.1007\/s00125-015-3622-8","journal-title":"Diabetologia"},{"key":"1220_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1010428317692204","volume":"39","author":"SJ Yang","year":"2017","unstructured":"Yang SJ, Yang SY, Wang DD et al (2017) The miR-30 family: versatile players in breast cancer. Tumor Biol 39:1\u201313. \u00a0\n                    https:\/\/doi.org\/10.1177\/1010428317692204","journal-title":"Tumor Biol"},{"key":"1220_CR27","doi-asserted-by":"publisher","first-page":"e53950","DOI":"10.1371\/journal.pone.0053950","volume":"8","author":"W Pan","year":"2013","unstructured":"Pan W, Zhong Y, Cheng C et al (2013) MiR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy. PLoS One 8:e53950. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0053950","journal-title":"PLoS One"},{"key":"1220_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11010-012-1552-z","volume":"379","author":"X Yin","year":"2013","unstructured":"Yin X, Peng C, Ning W et al (2013) miR-30a downregulation aggravates pressure overload-induced cardiomyocyte hypertrophy. Mol Cell Biochem 379:1\u20136. \n                    https:\/\/doi.org\/10.1007\/s11010-012-1552-z","journal-title":"Mol Cell Biochem"},{"key":"1220_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ilar.32.3.16","volume":"32","author":"RG Peterson","year":"1990","unstructured":"Peterson RG, Shaw WN, Neel MA, Little LA, Eichberg J (1990) Zucker diabetic fatty rat as a model for non-insulin dependent diabetes mellitus. ILAR J 32:16\u201319. \n                    https:\/\/doi.org\/10.1093\/ilar.32.3.16","journal-title":"ILAR J"},{"key":"1220_CR30","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/j.1476-5381.2012.01911.x","volume":"166","author":"AJ King","year":"2012","unstructured":"King AJ (2012) The use of animal models in diabetes research. Br J Pharmacol 166:877\u2013894. \n                    https:\/\/doi.org\/10.1111\/j.1476-5381.2012.01911.x","journal-title":"Br J Pharmacol"},{"key":"1220_CR31","doi-asserted-by":"publisher","first-page":"F1123","DOI":"10.1152\/ajprenal.00247.2014","volume":"307","author":"G Castoldi","year":"2014","unstructured":"Castoldi G, di Gioia CR, Bombardi C et al (2014) Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats. Am J Physiol Renal Physiol 307:F1123\u2013F1131. \n                    https:\/\/doi.org\/10.1152\/ajprenal.00247.2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"1220_CR32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/1440-1681.12532","volume":"43","author":"G Castoldi","year":"2016","unstructured":"Castoldi G, di Gioia CR, Giollo F et al (2016) Different regulation of miR-29a-3p in glomeruli and tubules in an experimental model of angiotensin II-dependent hypertension: potential role in renal fibrosis. Clin Exp Pharmacol Physiol 43:335\u2013342. \n                    https:\/\/doi.org\/10.1111\/1440-1681.12532","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1220_CR33","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1101\/gad.215939.113","volume":"27","author":"FV Karginov","year":"2013","unstructured":"Karginov FV, Hannon GJ (2013) Remodeling of Ago2-mRNA interactions upon cellular stress reflects miRNA complementarity and correlates with altered translation rates. Genes Develop 27:1624\u20131632. \n                    https:\/\/doi.org\/10.1101\/gad.215939.113","journal-title":"Genes Develop"},{"key":"1220_CR34","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1042\/CS20160491","volume":"131","author":"M Tate","year":"2017","unstructured":"Tate M, Grieve DJ, Ritchie RH (2017) Are targeted therapies for diabetic cardiomyopathy on the horizon? Clin Sci 131:897\u2013915. \n                    https:\/\/doi.org\/10.1042\/CS20160491","journal-title":"Clin Sci"},{"key":"1220_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40265-015-0509-4","volume":"76","author":"L Paulis","year":"2016","unstructured":"Paulis L, Foulquier S, Namsolleck P, Recarti C, Steckelings UM, Unger T (2016) Combined angiotensin receptor modulation in the management of cardio-metabolic disorders. Drugs 76:1\u201312. \n                    https:\/\/doi.org\/10.1007\/s40265-015-0509-4","journal-title":"Drugs"},{"issue":"2","key":"1220_CR36","doi-asserted-by":"publisher","first-page":"E197","DOI":"10.1152\/ajpendo.00149.2012","volume":"304","author":"M Shum","year":"2013","unstructured":"Shum M, Pinard S, Guimond MO et al (2013) Angiotensin II type 2 receptor promotes adipocyte differentiation and restores adipocyte size in high-fat\/high-fructose diet-induced insulin resistance in rats. Am J Physiol Endocrinol Metab 304(2):E197\u2013E210. \n                    https:\/\/doi.org\/10.1152\/ajpendo.00149.2012","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"11","key":"1220_CR37","doi-asserted-by":"publisher","first-page":"e48387","DOI":"10.1371\/journal.pone.0048387","volume":"7","author":"K Ohshima","year":"2012","unstructured":"Ohshima K, Mogi M, Jing F et al (2012) Direct angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPAR\u03b3 activation. PLoS One 7(11):e48387. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0048387","journal-title":"PLoS One"},{"issue":"3","key":"1220_CR38","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1210\/en.2013-1601","volume":"155","author":"C Shao","year":"2014","unstructured":"Shao C, Yu L, Gao L (2014) Activation of angiotensin type 2 receptors partially ameliorates streptozotocin-induced diabetes in male rats by islet protection. Endocrinology 155(3):793\u2013804. \n                    https:\/\/doi.org\/10.1210\/en.2013-1601","journal-title":"Endocrinology"},{"key":"1220_CR39","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/j.bbadis.2017.03.013","volume":"1863","author":"R Guo","year":"2017","unstructured":"Guo R, Nair S (2017) Role of microRNA in diabetic cardiomyopathy: from mechanism to intervention. BBA Mol Basis Dis 1863:2070\u20132077. \n                    https:\/\/doi.org\/10.1016\/j.bbadis.2017.03.013","journal-title":"BBA Mol Basis Dis"},{"key":"1220_CR40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/nyas.12758","volume":"1353","author":"M Kato","year":"2015","unstructured":"Kato M, Natarajan R (2015) MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets. Ann N Y Acad Sci 1353:72\u201388. \n                    https:\/\/doi.org\/10.1111\/nyas.12758","journal-title":"Ann N Y Acad Sci"},{"key":"1220_CR41","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.ejso.2013.11.008","volume":"40","author":"W Wang","year":"2014","unstructured":"Wang W, Lin H, Zhou L et al (2014) MicroRNA-30a-3p inhibits tumor proliferation, invasiveness and metastasis and is downregulated in hepatocellular carcinoma. EJSO 40:1586\u20131594. \n                    https:\/\/doi.org\/10.1016\/j.ejso.2013.11.008","journal-title":"EJSO"},{"key":"1220_CR42","doi-asserted-by":"publisher","first-page":"5885","DOI":"10.1007\/s13277-015-4456-1","volume":"37","author":"W Li","year":"2016","unstructured":"Li W, Dai H, Ou Q, Zuo GQ, Liu CA (2016) Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH\/PTEN\/AKT pathway. Tumor Biol 37:5885\u20135895. \n                    https:\/\/doi.org\/10.1007\/s13277-015-4456-1","journal-title":"Tumor Biol"},{"key":"1220_CR43","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/cvr\/cvp014","volume":"82","author":"GY Oudit","year":"2009","unstructured":"Oudit GY, Penninger JM (2009) Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res 82:250\u2013260. \n                    https:\/\/doi.org\/10.1093\/cvr\/cvp014","journal-title":"Cardiovasc Res"},{"key":"1220_CR44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.peptides.2013.06.008","volume":"47","author":"S Gao","year":"2013","unstructured":"Gao S, Park BM, Cha SA, Park WH, Park BH, Kim SH (2013) Angiotensin AT2 receptor agonist stimulates high stretch induced- ANP secretion via PI3K\/NO\/sGC\/PKG\/pathway. Peptides 47:36\u201344. \n                    https:\/\/doi.org\/10.1016\/j.peptides.2013.06.008","journal-title":"Peptides"},{"issue":"12","key":"1220_CR45","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1097\/01.hjh.0000251902.85675.7e","volume":"24","author":"C Savoia","year":"2006","unstructured":"Savoia C, Ebrahimian T, He Y, Gratton JP, Schiffrin EL, Touyz RM (2006) Angiotensin II\/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. J Hypertens 24(12):2417\u20132422. \n                    https:\/\/doi.org\/10.1097\/01.hjh.0000251902.85675.7e","journal-title":"J Hypertens"},{"key":"1220_CR46","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.bcp.2018.03.020","volume":"152","author":"A S\u00e1nchez","year":"2018","unstructured":"S\u00e1nchez A, Contreras C, Climent B et al (2018) Impaired Ca2+ handling in resistance arteries from genetically obese Zucker rats: Role of the PI3K, ERK1\/2 and PKC signaling pathways. Biochem Pharmacol 152:114\u2013128. \n                    https:\/\/doi.org\/10.1016\/j.bcp.2018.03.020","journal-title":"Biochem Pharmacol"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-018-1220-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-018-1220-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-018-1220-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T19:23:30Z","timestamp":1567625010000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-018-1220-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,5]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["1220"],"URL":"https:\/\/doi.org\/10.1007\/s00592-018-1220-1","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,5]]},"assertion":[{"value":"25 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Animal studies were in conformity with the Institutional Guidelines in compliance with National laws and policies (D.L.n. 116, Gazzetta Ufficiale della Repubblica Italiana, suppl.40, Feb.18, 1992) and experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study (experimental study on animal model) it is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}